Doxil® plus Eloxatin® Highly Active in Recurrent Ovarian Cancer

Doxil® plus Eloxatin® Highly Active in Recurrent Ovarian Cancer

According to an article recently published in Gynecologic Oncology, the chemotherapy combination consisting of Doxil® (pegylated liposomal doxorubicin) plus Eloxatin® (oxaplatin) provides high anticancer activity in patients with recurrent ovarian cancer.

Ovarian cancer is the leading cause of gynecologic cancer-related death in the United States. Relapsed ovarian cancer refers to cancer that has returned or progressed following prior therapies. Taxanes and platinums are types of chemotherapy agents commonly used in the treatment of ovarian cancer. Once patients with ovarian cancer have relapsed following taxanes and platinums, treatment options are limited. Researchers continue to evaluate novel chemotherapy combinations for this disease, which is difficult to treat .

Doxil belongs to a class of chemotherapy agents referred to as anthracyclines. Doxil is specifically created to deliver more chemotherapy to the cancer cells than to healthy tissues. As a result, side effects from the active ingredient in Doxil are limited while the agent’s anticancer activity is maintained. Eloxatin is a chemotherapy agent commonly used in the treatment of colorectal cancer.

Researchers from Italy recently conducted a clinical trial to evaluate the effectiveness of Doxil plus Eloxatin in 40 patients with recurrent ovarian cancer.

• Regression of cancer was achieved in 68% of patients.

• Disease stabilization occurred in 30% of patients.

• Median progression-free survival was 9.6 months.

• Median overall survival was 18.3 months.

• The main side effects were low levels of immune cells and changes to the skin on the palms of the hands and soles of the feet.

The researchers concluded that the chemotherapy combination consisting of Doxil and Eloxatin provides significant anticancer activity in patients with recurrent ovarian cancer. Patients with recurrent ovarian cancer may wish to speak with their physician regarding their individual risks and benefits of participation in a clinical trial further evaluating Doxil/Eloxatin or other promising therapeutic approaches. Two sources of information regarding ongoing clinical trials include the National Cancer Institute (www.cancer.gov) and www.eCancerTrials.com.

Reference: Recchia F, Saggio G, Amiconi G, et al. A multicenter Phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer. Gynecologic Oncology. 2007; 106:164-169.

Copyright © 2018 CancerConnect. All Rights Reserved.

Comments

Stories